Abstract OBJECTIVE: For patients in advanced heart failure, emergency transplantation or ventricular assist devices (VADs) are possible strategies. The aim of this single-centre, retrospective study was to evaluate early and long-term results for these two strategies.
INTRODUCTION
Heart transplantation is the solution of choice for advanced heart failure unresponsive to medical treatment. In selected cases, it improves both survival and quality of life [1] . The prognosis of these patients may, however, be poor because of the small number of donors and the consequently long waiting list. In Italy, in 2005, the reduced number of heart transplants led the National Transplant Organization (CNT) to create a ranking of priorities among patients on the waiting list based on clinical conditions, as had been done in the USA (with United Network for Organ Sharing status) in 1989 and in Germany in 2000 [2] [3] [4] . At present, in Italy, in order to access the urgent transplant programme, patients must be on inotropic support, ventilated and with a mechanical circulatory support; alternatively, they have to be on biventricular assistance or with complicated long-term circulatory support [5] . A patient who matches these criteria is eligible the first compatible organ and is suitable for transplantation available in any Italian intesive care unit (ICU).
Clearly, the opportunity of being enrolled into the emergency programme gives a chance of survival to critically ill patients; however, the low number of transplants performed has led to a progressive increase of heart transplants (HTx) performed as urgent procedures in patients often in poor clinical condition. It is well known that urgent transplantation may be associated with slightly worse results compared with elective transplantation [6, 7] and with a higher incidence of severe complications, such as primary graft failure, need for intra-aortic balloon pump, more prolonged mechanical ventilation time and renal replacement therapy, as well as a greater number of bacterial infections and a significantly longer ICU stay [8] [9] [10] .
The use of ventricular assist devices (VADs) as a bridge to transplantation (BTT) or to candidacy (BTC) has greatly influenced the management of emergency programmes. Many centres, rather than directly accessing the urgent programme, use VADs to stabilize critically ill patients and to provide more time to select the best treatment, especially for 'unknown' patients. Patients on VAD support are not included in the group of critically ill patients who need urgent HTx until the occurrence of device-related complications. In BTT patients, VADs improve organ function, optimizing the general condition of the patients at the time of transplantation. Whether these factors may have positive effects on post-transplant outcomes remains controversial [11] [12] [13] .
In the present study, we analysed data from critically ill patients who were implanted with a VAD as a BTC and compared them with those of patients who underwent emergency transplantation.
PATIENTS AND METHODS
Between 2005 and 2011 at our institution, 55 patients with advanced heart failure [Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS)-level 1 or 2] were admitted in our ICU. Six of them were not included in this study because of severe neurological status (glasgow coma scale ≤3), irreversible renal or hepatic dysfunction (total bilirubin >7 mg/dl or creatinine >4 mg/dl) or sepsis (Fig. 1) . The remaining 49 patients [36 (73.5%) were male] were considered for the study. The age of patients included in the study ranged from 14 to 70 years, with a mean of 51 ± 14 years.
Patients were divided into two groups: group A comprised 26 (53%) patients who were included in the urgent heart transplant waiting list; and group B comprised 23 (47%) patients who underwent VAD implantation on an emergency basis (Fig. 1) .
Preoperative characteristics of both groups are listed in Table 1 . In group A, there was more severe dysfunction of the right ventricle, with a lower right ventricular stroke work index (5.20 vs 7.52 g m/m 2 /beat; P = 0.03) and higher pulmonary vascular resistance (2.99 vs 2.25 Wood units; P = 0.05). In patients on extracorporeal membrane oxygenation (ECMO), the right ventricular function was evaluated with a transoesophageal echocardiographic examination and Swan-Ganz catheter pressure monitoring, after reducing the ECMO assistance to a minimum of 0.5 l/min for 30 min. The serum creatinine level was significantly higher in group A (2.19 vs 1.46 mg/dl; P = 0.05).
Statistical analysis and limitations
This is a single-centre, retrospective, not blinded and not randomized study. Decision criteria used to assign patients to one or the other treatment (emergency transplantation or VAD implantation) were influenced by the growing experience in the centre regarding VAD implantation and management in critical patients in recent years. In the first phase of the study, patients were more frequently enrolled on the urgent transplant waiting list, while in more recent years they were treated preferentially with emergency long-term VAD implantation.
In every graph, 30 day mortality and in-hospital mortality were included in the overall mortality analysis.
RESULTS

Early results
In group A, one patient died before transplantation, while 25 patients underwent transplantation. The mean time on the waiting list for the patients who underwent transplantation was 2.73 ± 2.23 days (range 0.5-9 days). Mortality on the waiting list before receiving heart transplantation was 3.8%. No differences have been shown, in terms of characteristics of the donors, between transplants performed in patients on the urgent waiting list and transplants performed in patients on the ordinary waiting list (Table 2) .
In group B, four biventricular VADs (BiVADs; Excor Berlin Heart-Berlin, Germany) and 19 left ventricular assist devices (LVADs) (17 Incor Berlin Heart-Berlin, Germany; 2 HVAD Heartware) were implanted as a BTT or as a BTC.
In-hospital mortality was significantly higher in group A (42.3 vs 4.3%; P = 0.002). Considering only the group A patients who underwent transplantation, in-hospital mortality was 41.2%. 
Long-term results
The mean follow-up time was 21.7 ± 26.3 months (range 1 day to 6.4 years) for group A and 9.36 ± 3.6 months (range 16 days to 2.4 years) for group B.
Long-term survival for patients who underwent VAD implantation and were not censored for heart transplantation (23 patients) was 87% at 6 months, 77% at 12 months, 66% at 18 months and 55% at 24 months. Survival at 6 and 12 months of VAD-implanted patients (not censored for heart transplantation) was significantly higher than in patients who were on the urgent waiting list (26 patients; 53% at 6 months, P = 0.02; and 48% at 12 months, P = 0.04) and in patients on the urgent waiting list who underwent transplantation (25 of 26 patients; 55% at 6 months P = 0.02; and 50% at 12 months, P = 0.05). No significant difference was observed at 18 and 24 months (P = 0.14; P = 0.34 respectively; Fig. 2 ).
Kaplan-Meier survival curves showed a lower survival of group A at 6, 12 and 18 months with respect to group B Figure 1 : The flow chart shows the surgical treatments that were carried out on two groups of patients. Group A comprised 26 patients including in the waiting list for heart transplantation with urgent conditions. Group B comprised 23 patients who underwent VAD implantation as a bridge to candidacy with urgent conditions. BiVAD: biventricular assist device; BTR: bridge to recovery; BTT: bridge to transplantation; DT: destination therapy.
censored at the time of transplantation. This difference was significant only at 6 months (P = 0.02). (Fig. 3) .
In our series, there was no recovery of the native heart function under VAD support.
Causes and incidences of hospitalization in both groups are summarized in Table 3 . Morbidity and in-hospital re-admission were more frequent in group B. Main causes of hospitalization were: major driveline infections, VAD controller replacement and ischaemic or haemorrhagic neurological complications in group B; and infections, rejections and tumours in group A (Table 3) .
In group B, five patients were switched from BTC to destination therapy because of inelegibility for heart transplantation.
Thirteen (56.5%) patients supported by VAD underwent transplantation after a mean time of 9.1 ± 7.2 months. In five patients (38.5%), the transplant was done on an emergency basis for complications related to the assistance device (in three cases because of major local wound infection, in one case because ischaemic stroke occurred in a 16-year-old patient, and in one case because of left inflow cannula malpositioning). Four of these five (80%) patients were supported by a BiVAD. Elective heart transplantation was carried out in the remaining eight patients (61.5%), with a mean time on the waiting list of 11.1 ± 6.3 months (range 2.5-20.8 months). None of these eight patients transplanted electively died in hospital. In-hospital mortality after heart transplantation in group B (13 patients) was 15.4%.
In group B, good long-term results were limited by serious adverse events, such as major driveline infections and cerebral vascular accident (CVA), i.e. ischaemic stroke and haemorrhagic stroke. Kaplan-Meier curves of freedom from these major events are shown in Fig. 4 .
The cumulative actuarial survival in group B shows that at 1 year following VAD implantation more than 50% of patients were ongoing ( patient alive with device in place). Mortality increased after 1 year of ventricular support from 12 to 22% (Fig. 5 ). 
DISCUSSION
In our experience, emergency VAD implantation has been a viable alternative to urgent heart transplantation, avoiding the related high risk of mortality. As this study has shown, haemodynamic stabilization of critically ill patients can enable them to undergo elective cardiac transplantation (gold standard therapy) with good results. Newer indications of VAD implantation include medium-and long-term support in order to avoid the premature assignment to transplantation with uncertain results (recipient-donor optimization). The purpose of the use of VADs in INTERMACS 1 and 2 patients is to overcome the critical stage and perform the heart transplant as an elective procedure and, thus, in better conditions. The analysis of our data shows that the advantage gained by the implantation of VADs is significant only if patients are transplanted electively within 12 months. High morbidity (caused by major driveline infections, ischaemic and haemorrhagic stroke during the follow-up period) reduces the survival beyond 1 year and limits the efficacious long-term use of these devices.
Improvements in outcomes with mechanical circulatory support for patients requiring LVAD have been universally acknowledged during the past decade [14] . However, for patients requiring biventricular support (BiVAD), outcomes still remain far inferior. Data from INTERMACS show that the presence of a BiVAD has a strong adverse effect on outcomes, with these These results refer to the use of paracorporeal BiVAD (like Excor Berlin Heart or Medos Thoratec) or total artificial heart. It is likely that in the future BiVAD implantation may have better results thanks to the recent use of continous-flow LVAD adapted on the right side. The feasibility of implantation of two Heartware HVAD centrifugal pumps as a biventricular device has been reported since 2010 from many centres, but the long termresults of this non-standardized procedure are yet known.
In our experience, four patients were supported by a BiVAD, and in all cases, they were transplanted on an emergency basis for a serious complication of the VAD after a mean time of 73 ± 10.9 days (range 9-222 days). The BiVAD exposes patients to a high risk of a urgent transplant procedure.
The limitations of this retrospective single-centre study are related to the restricted number of patients, and the decision criteria used to assign patients to one or other treatment (emergency transplantation or VAD implantation) were influenced by the growing experience of the centre concerning VAD implantation and management, although in critical patients, in recent years. Prospective multicentre, randomized studies should be undertaken in order to confirm outcomes and to define more clear indications/guidelines in such groups of critically ill patients.
In conclusion, in INTERMACS 1 and 2 patients, in the case of severe left ventricular dysfunction, the use of a mechanical assistance device may be the best choice. In the case of severe biventricular dysfunction, in a patient with a clear contraindication to heart transplantation, a BiVAD using two centrifugal pumps as destination therapy may be a solution. Long-term results are uncertain in this specific condition. In young patients, urgent heart transplantation may still be the best choice or, alternatively, biventricular mechanical assistance could be used for a short period of time (not longer than 30-60 days) in order to allow heart transplantation in the best patient conditions and, in particular, without acute haemodynamic impairment.
APPENDIX. CONFERENCE DISCUSSION
Dr S. Westaby (Oxford, UK): I thought this was a very interesting study, but actually would have preferred to have seen a prospective randomized trial of emergency transplantation vs. bridge to transplantation.
I took away some important messages from your paper. The first one was that even with very good-quality donor hearts, your 1 year mortality for emergency cardiac transplantation was more than 50%. Secondly, patients that were supported and bridged with a VAD to reverse multiple organ failure before transplantation actually did much better, with hospital mortality of 15%. Thirdly, after 1 year of VAD support, your results started to deteriorate because of VAD-related complications. This was very disappointing, since you were using the INCOR and the HeartWare VADs that are destination therapy VADs, but you still had a lot of problems with them. The last point was that the need for biventricular support in every single series conveys very high mortality.
I have two questions. First, because donor hearts are scarce, can it still be justified to use them as primary treatment for status 1 patients with multiple organ failure? Second, the implantable VADs cost the same as a Porsche car. Why not use the well-tried and tested temporary VADs for bridge-to-transplantation, since you can get your donor hearts in a relatively short time? Why not reverse multiple organ failure with inexpensive VADs Figure 5 : The cumulative actuarial survival in group B shows that at 1 year following VAD implantation, more than 50% of patients were ongoing ( patient alive with device in place). Mortality increased after 1 year of ventricular support from 12 to 22%.
